Tag:
patent rules
Latest Headlines
Latest Headlines
U.S. questions India's IP regime after Nexavar move
Is intellectual property safe in India? That's the question drugmakers--and now U.S. officials--are asking.
Indian government forces Bayer to accept generic Nexavar competition
India has invoked its compulsory licensing rules for the first time, allowing the domestic drugmaker Natco Pharma to make and sell a version of Bayer's cancer drug Nexavar--despite the fact that...
U.S. Senate overwhelmingly OKs patent revamp
The U.S. Senate has passed a patent-reform bill that had been backed by branded drugmakers but opposed by generic companies in an 89-9 vote. President Obama is expected to sign it. Report
In bombshell, DOJ reverses stance on gene patents
The U.S. Justice Department dropped a bombshell on the biotech industry late Friday, saying that unmodified DNA should not be patentable. Federal attorneys outlined the policy shift in a
Indian court dismisses Bayer's patent claim
In a landmark case that has sparked a heated debate about patent linkage in India, Delhi's high court today threw out Bayer's petition to block Indian generics maker Cipla from gaining regulatory
Apotex isn't giving up the ghost on Plavix
Apotex may just be the little Canadian drugmaker that could. Despite all the evidence, the company still thinks it can knock down the patent on Plavix, the top-earning blood thinner marketed by
Glaxo reviews options in patent-rule loss
Remember the patent-rule fight GlaxoSmithKline led on behalf of the pharma industry? Glaxo et al prevailed in a court challenge to some new regs that would have affected both initial patent filings
ALSO NOTED: Apoptos gains $28M Series A; Commonwealth Biotechnologies venture to recruit 1,000 chemists in China;and much more.
> Apoptos will get a two-tranche Series A of $28 million from a group of investors that includes Venrock, ARCH Venture Partners, OrbiMed Advisors, and Advanced Technology Ventures. The developer
Patent rules create new biotech hazards
The Scientist examines the impact of new patent rules that take effect on November 1, saying the shift streamlines the process but will make it more expensive for biotech companies and
